Published on 10 Aug 2022 on Zacks via Yahoo Finance
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
Lumos Pharma (LUMO) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.04 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 4.08%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.92 per share when it actually produced a loss of $0.92, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.